Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.
AT132 has prompted more safety concerns, this time at a lower dose than before.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.